Sihuan Pharmaceutical

Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province.^[1] The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.

Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease.^[1] The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan.^[2]

References[]

^ ^a ^b Patti Waldmeir and Lucy Hornby (9 October 2014). "Chinese company develops Ebola treatment". Financial Times. Retrieved 4 January 2015.
^ Nakanishi, Azusa (11 December 2014). "Copycats put squeeze on Japanese drugmakers". Chicago Tribune. Retrieved 4 January 2015.

External links[]

http://www.sihuanpharm.com/

This pharmacology-related article is a stub. You can help Wikipedia by .

This Chinese corporation or company article is a stub. You can help Wikipedia by .

[ft9oct2014-1] Patti Waldmeir and Lucy Hornby (9 October 2014). "Chinese company develops Ebola treatment". Financial Times. Retrieved 4 January 2015.

[2] Nakanishi, Azusa (11 December 2014). "Copycats put squeeze on Japanese drugmakers". Chicago Tribune. Retrieved 4 January 2015.

[1]

[2]